Belharra Therapeutics Email Format

Biotechnology ResearchCalifornia, United States11-50 Employees

Belharra Therapeutics, Inc. is a privately held biotechnology research company focused on drug discovery, employing a photoaffinity-based chemoproteomics platform to identify small-molecule drug candidates for any binding site on any protein, in any conformational state, and in any cell type. The company is headquartered in the San Francisco Bay Area and maintains its primary lab and offices in San Diego, California, at 3985 Sorrento Valley Boulevard, San Diego 92121. It was founded in 2021 by Christopher G. Parker, John Teijaro, Benjamin Cravatt, and Stuart Schreiber, co-founders affiliated with Scripps Research and the Broad Institute, and began with a $50 million Series A financing from Versant Ventures and incubation at Inception Therapeutics. The organization has 11-50 employees. In recent years, Belharra has engaged in external collaborations and leadership appointments, including a strategic collaboration with Sanofi announced in June 2024 and the appointment of Sean Buchanan, Ph.D., as Chief Scientific Officer in January 2025.

Get verified Belharra Therapeutics emails free

Company overview Employee directory